Contact
 

The Canadian Health Minister, Leona Aglukkaq, announced Dr. Bhagirath Singh and Dr. Jose Esparza as Co-chairs of the Advisory Board that will oversee the renewed Canadian HIV Vaccine Initiative (CHVI) and its Research and Development Alliance....

The National Institutes of Health (NIH) issued a statement on the iPrEx study results, http://www.niaid.nih.gov/news/newsreleases/2010/Pages/iPrEx.aspx.  ...

The HVTN released a statement on the iPrEx study results, stating that "PrEP is an exciting addition to the “toolbox” of HIV prevention strategies."  The full statement is available below.

“This is a great day in the fight against AIDS. The positive results of the iPrEx oral PrEP study are a major milestone in HIV prevention research and provide important information about how antiretroviral drugs might be used for prevention byHIV...

The Global HIV Vaccine Enterprise released a statement today on the announcement of the results of the first study of oral pre-exposure prophylaxis (PrEP) for HIV prevention in humans.  "The iPrEx study, is a very important addition to what...

Organizer: Uganda Virus Research Institute (UVRI) and International Aids Vaccine Initiative (IAVI)

Location: Kasenyi landing site, Entebbe, Uganda
Date/Time: Monday, 29 November, 9:00 – 13:00...

The Council of the Global HIV Vaccine Enterprise issued the below statement today regarding the resignation of one of its founding members, Dr. Margaret (Peggy) Johnston, from the Vaccine Research Program at the U.S. National Institute of Allery...

The National Institute of Allergy and Infectious Diseases is funding a third round of the novel research initiative entitled “The Early Stage Investigator Scholar Award: Pilot Studies to Advance Non-Human Primate Models in Support of HIV Vaccine...

The hottest news in AIDS in the last year was the partial success in a South African clinical trial of a microbicide.  Read the full New York Times article by Donald McNeil regarding the promise of microbicides upcoming PrEP results...

A new study published online in Science found that slight differences in the structure of a protein in the body that recognizes HIV could explain why some individuals infected with HIV are able to resist the onset of AIDS without treatment....

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account